Abivax S.A.

Abivax appoints Mark Stenhouse, former COO of Prometheus Biosciences, as Board Observer and Advisor. Stenhouse brings over 30 years of biopharma experience, including roles at AbbVie and Exact Sciences. His expertise in gastroenterology and immunology is expected to support Abivax's progress toward commercializing obefazimod, its lead drug candidate for ulcerative colitis and Crohn's disease.

Abivax terminated its liquidity contract with TRADITION SECURITIES AND FUTURE (TSAF SA) on September 30, 2024, with €434,377.26 in cash and 0 shares remaining. The contract, initially signed on February 4, 2019, saw 12,501 shares sold and 1,070 shares bought between July 1, 2024, and September 30, 2024.

Abivax congratulates Victor Ambros and Gary Ruvkun on their Nobel Prize for microRNA discovery, highlighting its role in gene regulation. Abivax's lead candidate, obefazimod, leverages microRNA-124 to treat chronic inflammatory diseases like ulcerative colitis and Crohn's disease.

The article content is not provided for summarization.

Abivax enrolls first patient in Phase 2b ENHANCE-CD trial evaluating obefazimod for Crohn's disease, aiming to provide effective treatments for patients.

Abivax announced the first patient enrolled in its Phase 2b ENHANCE-CD trial evaluating obefazimod for Crohn’s disease. The trial is a multicenter, double-blind, randomized, placebo-controlled study with a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase, aiming to assess obefazimod’s efficacy and safety in adults with moderately to severely active Crohn’s disease.

Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to the ARTEMIS-UC trial. The study incorporated a predictive biomarker for response, showing significant clinical remission, endoscopic improvement, and clinical response in patients on tulisokibart compared to placebo. A phase 3 program is planned to confirm these results.